vs
Side-by-side financial comparison of IDEAYA Biosciences, Inc. (IDYA) and TechTarget, Inc. (TTGT). Click either name above to swap in a different company.
IDEAYA Biosciences, Inc. is the larger business by last-quarter revenue ($207.8M vs $140.7M, roughly 1.5× TechTarget, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs -6.7%, a 64.1% gap on every dollar of revenue. IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $11.6M).
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
TechTarget, Inc. is an American company that offers data-driven marketing services to business-to-business technology vendors.
IDYA vs TTGT — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $207.8M | $140.7M |
| Net Profit | $119.2M | $-9.5M |
| Gross Margin | — | 63.8% |
| Operating Margin | 52.2% | -10.5% |
| Net Margin | 57.4% | -6.7% |
| Revenue YoY | — | — |
| Net Profit YoY | 330.1% | — |
| EPS (diluted) | $1.33 | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $140.7M | ||
| Q3 25 | $207.8M | $122.3M | ||
| Q2 25 | — | $119.9M | ||
| Q1 25 | — | $103.9M | ||
| Q3 24 | $0 | $62.9M | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $0 | — | ||
| Q3 22 | $29.7M | — |
| Q4 25 | — | $-9.5M | ||
| Q3 25 | $119.2M | $-76.8M | ||
| Q2 25 | — | $-398.7M | ||
| Q1 25 | — | $-523.4M | ||
| Q3 24 | $-51.8M | $-17.4M | ||
| Q2 24 | $-52.8M | — | ||
| Q1 24 | $-39.6M | — | ||
| Q3 22 | $1.6M | — |
| Q4 25 | — | 63.8% | ||
| Q3 25 | — | 61.3% | ||
| Q2 25 | — | 57.3% | ||
| Q1 25 | — | 57.5% | ||
| Q3 24 | — | 62.1% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | — | — |
| Q4 25 | — | -10.5% | ||
| Q3 25 | 52.2% | -88.2% | ||
| Q2 25 | — | -342.1% | ||
| Q1 25 | — | -474.5% | ||
| Q3 24 | — | -22.9% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | 2.2% | — |
| Q4 25 | — | -6.7% | ||
| Q3 25 | 57.4% | -62.8% | ||
| Q2 25 | — | -332.4% | ||
| Q1 25 | — | -503.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | 5.4% | — |
| Q4 25 | — | $-0.09 | ||
| Q3 25 | $1.33 | $-1.07 | ||
| Q2 25 | — | $-5.58 | ||
| Q1 25 | — | $-7.32 | ||
| Q3 24 | $-0.60 | $-0.42 | ||
| Q2 24 | $-0.68 | — | ||
| Q1 24 | $-0.53 | — | ||
| Q3 22 | $0.04 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $786.9M | $40.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $594.6M |
| Total Assets | $1.2B | $937.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.6M | ||
| Q3 25 | $786.9M | $46.3M | ||
| Q2 25 | — | $61.7M | ||
| Q1 25 | — | $78.7M | ||
| Q3 24 | $920.0M | — | ||
| Q2 24 | $701.7M | — | ||
| Q1 24 | $698.8M | — | ||
| Q3 22 | $386.2M | — |
| Q4 25 | — | $594.6M | ||
| Q3 25 | $1.1B | $597.9M | ||
| Q2 25 | — | $668.7M | ||
| Q1 25 | — | $1.1B | ||
| Q3 24 | $1.2B | $134.2M | ||
| Q2 24 | $931.7M | — | ||
| Q1 24 | $935.3M | — | ||
| Q3 22 | $368.8M | — |
| Q4 25 | — | $937.3M | ||
| Q3 25 | $1.2B | $987.4M | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.5B | ||
| Q3 24 | $1.2B | $0 | ||
| Q2 24 | $973.7M | — | ||
| Q1 24 | $961.5M | — | ||
| Q3 22 | $410.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.2M | $11.8M |
| Free Cash FlowOCF − Capex | $142.2M | $11.6M |
| FCF MarginFCF / Revenue | 68.4% | 8.2% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.19× | — |
| TTM Free Cash FlowTrailing 4 quarters | $13.5M | $15.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $11.8M | ||
| Q3 25 | $142.2M | $-9.1M | ||
| Q2 25 | — | $1.5M | ||
| Q1 25 | — | $12.2M | ||
| Q3 24 | $-49.2M | — | ||
| Q2 24 | $-32.9M | — | ||
| Q1 24 | $-43.8M | — | ||
| Q3 22 | $-24.2M | — |
| Q4 25 | — | $11.6M | ||
| Q3 25 | $142.2M | $-9.3M | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | $12.2M | ||
| Q3 24 | $-49.7M | — | ||
| Q2 24 | $-33.9M | — | ||
| Q1 24 | $-45.1M | — | ||
| Q3 22 | $-25.3M | — |
| Q4 25 | — | 8.2% | ||
| Q3 25 | 68.4% | -7.6% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 11.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | -85.1% | — |
| Q4 25 | — | 0.1% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | 3.7% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | -14.96× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
